BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

580 related articles for article (PubMed ID: 26768192)

  • 21. Indications of 24-h esophageal pH monitoring, capsule pH monitoring, combined pH monitoring with multichannel impedance, esophageal manometry, radiology and scintigraphy in gastroesophageal reflux disease?
    Vardar R; Keskin M
    Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S16-S21. PubMed ID: 29199161
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Psychosocial Distress and Quality of Life Impairment Are Associated With Symptom Severity in PPI Non-Responders With Normal Impedance-pH Profiles.
    Yadlapati R; Tye M; Keefer L; Kahrilas PJ; Pandolfino JE
    Am J Gastroenterol; 2018 Jan; 113(1):31-38. PubMed ID: 28895583
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined esophageal multichannel intraluminal impedance and pH monitoring (MII -pH) in the diagnostics and treatment of gastroesophageal reflux disease and its complications.
    Masiak W; Wallner G; Wallner J; Pedowski T; Solecki M
    Pol Przegl Chir; 2011 Sep; 83(9):488-96. PubMed ID: 22166737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Most Patients With Gastroesophageal Reflux Disease Who Failed Proton Pump Inhibitor Therapy Also Have Functional Esophageal Disorders.
    Abdallah J; George N; Yamasaki T; Ganocy S; Fass R
    Clin Gastroenterol Hepatol; 2019 May; 17(6):1073-1080.e1. PubMed ID: 29913281
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors.
    Becker V; Grotz S; Schlag C; Nennstiel S; Beitz A; Haller B; Schmid RM; Meining A; Bajbouj M
    World J Gastroenterol; 2014 Apr; 20(14):4017-24. PubMed ID: 24744591
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection.
    Kawami N; Takenouchi N; Umezawa M; Hoshino S; Hanada Y; Hoshikawa Y; Sano H; Hoshihara Y; Nomura T; Uchida E; Iwakiri K
    Digestion; 2017; 95(2):140-145. PubMed ID: 28161707
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Post-reflux swallow-induced peristaltic wave index and mean nocturnal baseline impedance predict PPI response in GERD patients with extra esophageal symptoms.
    Ribolsi M; Guarino MPL; Tullio A; Cicala M
    Dig Liver Dis; 2020 Feb; 52(2):173-177. PubMed ID: 31623954
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring.
    Mainie I; Tutuian R; Shay S; Vela M; Zhang X; Sifrim D; Castell DO
    Gut; 2006 Oct; 55(10):1398-402. PubMed ID: 16556669
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Multichannel intraluminal impedance in the evaluation of patients with persistent globus on proton pump inhibitor therapy.
    Anandasabapathy S; Jaffin BW
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):563-70. PubMed ID: 16944654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical, but not oesophageal pH-impedance, profiles predict response to proton pump inhibitors in gastro-oesophageal reflux disease.
    Zerbib F; Belhocine K; Simon M; Capdepont M; Mion F; Bruley des Varannes S; Galmiche JP
    Gut; 2012 Apr; 61(4):501-6. PubMed ID: 21997546
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Predicting the efficacy of proton pump inhibitors in patients with non-erosive reflux disease before therapy using dual-channel 24-h esophageal pH monitoring.
    Shimatani T; Sugimoto M; Nishino M; Adachi K; Furuta K; Ito M; Kurosawa S; Manabe N; Mannen K; Hongo M; Chiba T; Kinoshita Y;
    J Gastroenterol Hepatol; 2012 May; 27(5):899-906. PubMed ID: 22098590
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Convenient Method of Measuring Baseline Impedance for Distinguishing Patients with Functional Heartburn from those with Proton Pump Inhibitor-Resistant Endoscopic Negative Reflux Disease.
    Yoshimine T; Funaki Y; Kawamura Y; Tamura Y; Izawa S; Ebi M; Ogasawara N; Murotani K; Sasaki M; Kasugai K
    Digestion; 2019; 99(2):157-165. PubMed ID: 30179879
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The role of gastroesophageal reflux in relation to symptom onset in patients with proton pump inhibitor-refractory nonerosive reflux disease accompanied by an underlying esophageal motor disorder.
    Izawa S; Funaki Y; Iida A; Tokudome K; Tamura Y; Ogasawara N; Sasaki M; Kasugai K
    Digestion; 2014; 89(1):61-7. PubMed ID: 24458115
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [The characteristics of esophagogastric junction contractile index in patients with gastroesophageal reflux disease or functional heartburn].
    Wang K; Duan LP; Ge Y; Xia ZW; Xu ZJ
    Zhonghua Nei Ke Za Zhi; 2016 Apr; 55(4):283-8. PubMed ID: 27030616
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of reflux frequency during prolonged multichannel intraluminal impedance and pH monitoring on and off acid suppression therapy.
    Blonski W; Vela MF; Castell DO
    J Clin Gastroenterol; 2009 Oct; 43(9):816-20. PubMed ID: 19398927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevalence and clinical characteristics of refractoriness to optimal proton pump inhibitor therapy in non-erosive reflux disease.
    Ribolsi M; Cicala M; Zentilin P; Neri M; Mauro A; Efthymakis K; Petitti T; Savarino V; Penagini R
    Aliment Pharmacol Ther; 2018 Nov; 48(10):1074-1081. PubMed ID: 30294924
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing.
    Clayton SB; Rife CC; Singh ER; Kalbfleisch JH; Castell DO
    Dis Esophagus; 2012; 25(8):682-6. PubMed ID: 22292567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Correlation between reflux burden, peristaltic function, and mucosal integrity in GERD patients.
    Ribolsi M; Gyawali CP; Savarino E; Rogers B; Rengarajan A; Della Coletta M; Ghisa M; Cicala M
    Neurogastroenterol Motil; 2020 Mar; 32(3):e13752. PubMed ID: 31670453
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prolonged measurement improves the assessment of the barrier function of the esophago-gastric junction by high-resolution manometry.
    Jasper D; Freitas-Queiroz N; Hollenstein M; Misselwitz B; Layer P; Navarro-Rodriguez T; Fox M; Keller J
    Neurogastroenterol Motil; 2017 Feb; 29(2):. PubMed ID: 27523737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical utility of salivary pepsin measurement in patients with proton pump inhibitor-refractory gastroesophageal reflux disease symptoms: a prospective comparative study.
    Matsumura T; Arai M; Suzuki T; Hoppo T; Seki Y; Kasamatsu S; Ishigami H; Ishikawa K; Okimoto K; Akizue N; Maruoka D; Nakagawa T; Odaka T; Okamoto Y; Kato N
    Esophagus; 2020 Jul; 17(3):339-347. PubMed ID: 31982992
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 29.